TNFA — TNF Pharmaceuticals Balance Sheet
0.000.00%
- $2.04m
- -$6.48m
Annual balance sheet for TNF Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 35.3 | 11.6 | 4.84 | 4.92 | 8.52 |
Net Total Receivables | 1.2 | — | — | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 36.8 | 12.7 | 5.4 | 5.82 | 9.41 |
Net Property, Plant And Equipment | — | 0.149 | 0.14 | 0.047 | 0.011 |
Net Goodwill | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 36.8 | 24.8 | 17.5 | 17.9 | 21.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.26 | 1.04 | 2.77 | 4.99 | 6.7 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.26 | 1.17 | 2.84 | 5.09 | 6.7 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 34.6 | 23.6 | 14.7 | 12.8 | 14.7 |
Total Liabilities & Shareholders' Equity | 36.8 | 24.8 | 17.5 | 17.9 | 21.4 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |